News
-
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Valneva SE reports positive Phase 1 trial results for VLA1601, its second-generation Zika vaccine candidate, showing improved immune response. Safety and immunogenicity demonstrated in trial